经血来源的间充质干细胞治疗早发性卵巢功能不全的进展

Research Progress of Menstrual Blood-Derived Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

大多数早发性卵巢功能不全患者由于卵巢储备减少而表现为生育力降低,随着再生医学的发展,各种间充质干细胞越来越被考虑用于治疗早发性卵巢功能不全。其中,经血来源的间充质干细胞能够通过分化为靶向外源细胞、靶向损伤部位的归巢和植入、外泌体有效分泌一系列旁分泌细胞因子等机制改善卵巢功能,促进生育力的恢复,并具有来源丰富、非侵入性获取和免疫原性低等优点,被认为有希望作为治疗早发性卵巢功能不全的新方法,但经血来源的间充质干细胞移植在临床治疗中的应用尚不广泛。综述经血来源的间充质干细胞对卵巢功能的影响以及治疗早发性卵巢功能不全的可能机制,为进一步研究和临床治疗提供理论依据。

Most patients with premature ovarian insufficiency exhibit reduced fertility due to reduced ovarian reserve.With the development of regenerative medicine,various mesenchymal stem cells are increasingly being considered for the treatment of premature ovarian insufficiency.Among them,mesenchymal stem cells derived from menstrual blood can improve ovarian function and promote the recovery of fertility by differentiating into targeting exogenous cells,targeting the homing and implantation of injured sites,and effective secretion of a series of parasecretory cytokines by exosomes,with the advantages of rich sources,non-invasive acquisition and low immunogenicity.It is considered as a promising new method for the treatment of premature ovarian insufficiency,but the clinical application of menstrual blood-derived mesenchymal stem cell transplantation is not yet widely used.This paper reviews the effects of menstrual blood-derived mesenchymal stem cells on ovarian function and the possible mechanisms of treating premature ovarian insufficiency,providing theoretical basis for further research and clinical treatment.